Large-scale Metabolomic Analysis Reveals Potential Biomarkers for Early Stage Coronary Atherosclerosis

• Published in: Scientific reports Vol. 7; no. 1; pp. 11817 - 11
• Main Authors: Gao, Xueqin, Ke, Chaofu, Liu, Haixia, Liu, Wei, Li, Kang, Yu, Bo, Sun, Meng
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18.09.2017; Nature Publishing Group
• Subjects: 631/337; 631/553/338; Arteriosclerosis; Atherosclerosis; Biomarkers; Cardiovascular disease; Coronary artery disease; Heart diseases; Humanities and Social Sciences; Lipid metabolism; Metabolites; Metabolomics; multidisciplinary; Occlusion; Phospholipids; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-12254-1

Coronary atherosclerosis (CAS) is the pathogenesis of coronary heart disease, which is a prevalent and chronic life-threatening disease. Initially, this disease is not always detected until a patient presents with seriously vascular occlusion. Therefore, new biomarkers for appropriate and timely diagnosis of early CAS is needed for screening to initiate therapy on time. In this study, we used an untargeted metabolomics approach to identify potential biomarkers that could enable highly sensitive and specific CAS detection. Score plots from partial least-squares discriminant analysis clearly separated early-stage CAS patients from controls. Meanwhile, the levels of 24 metabolites increased greatly and those of 18 metabolites decreased markedly in early CAS patients compared with the controls, which suggested significant metabolic dysfunction in phospholipid, sphingolipid, and fatty acid metabolism in the patients. Furthermore, binary logistic regression showed that nine metabolites could be used as a combinatorial biomarker to distinguish early-stage CAS patients from controls. The panel of nine metabolites was then tested with an independent cohort of samples, which also yielded satisfactory diagnostic accuracy (AUC = 0.890). In conclusion, our findings provide insight into the pathological mechanism of early-stage CAS and also supply a combinatorial biomarker to aid clinical diagnosis of early-stage CAS.